Breaking News Instant updates and real-time market news.

ATRS

Antares Pharma

$2.60

-0.04 (-1.52%)

, PFE

Pfizer

$40.53

0.87 (2.19%)

07:08
08/06/18
08/06
07:08
08/06/18
07:08

Antares Pharma enters into development with Pfizer

Antares Pharma (ATRS) announced that it has entered into an agreement with Pfizer (PFE) to develop a combination drug device rescue pen. This rescue pen will utilize the Antares QuickShot auto injector and an undisclosed Pfizer drug. Pfizer will pay for the development of the product and will be responsible for obtaining FDA approval of the combination product. The parties intend to enter into a separate supply agreement pursuant to which Antares will provide fully packaged commercial ready finished product to Pfizer at cost plus margin and Pfizer will then be responsible for commercializing the product in the United States, pending FDA approval. Antares will then receive royalties on net sales on the combination product.

ATRS

Antares Pharma

$2.60

-0.04 (-1.52%)

PFE

Pfizer

$40.53

0.87 (2.19%)

  • 07

    Aug

  • 22

    Aug

  • 10

    Sep

ATRS Antares Pharma
$2.60

-0.04 (-1.52%)

05/08/18
HCWC
05/08/18
NO CHANGE
Target $4
HCWC
Buy
Antares target raised to $4 on higher Xyosted confidence at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said that Antares Pharma reported "solid" Q1 results but "most importantly...finally explicitly confirmed a key aspect of the Xyosted filing," specifically that the company already conducted an ambulatory blood pressure monitoring study as part of the supplemental safety study ahead of the NDA submission. That fact, along with Antares' ability to re-submit the NDA just a week after receiving the minutes from the FDA Type-A meeting, increases his confidence in Xyosted approval coming in 2018, Livnat said. He raised his view of Xyosted's probability of success to 70% from 40% and increased his price target to $4 from $3.50 on Antares shares. Livnat keeps a Buy rating on the stock.
10/23/17
JANY
10/23/17
NO CHANGE
JANY
Neutral
Antares CRL doesn't raise issues for Amag Pharmaceuticals, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA complete response letter issued to Antares (ATRS) for Xyosted did not pertain to the Quickshot subcutaneous autoinjector, which raises his confidence the FDA will not identify such issues as a short coming of the sNDA for Amag Pharmaceuticals' (AMAG) Makena SQ. However, he keeps a Neutral rating on Amag shares, noting that the primary uncertainty for the sNDA for Makena SQ is the fact that its peak plasma levels is higher than the upper bound the FDA uses to define bioequivalence.
10/23/17
RAJA
10/23/17
NO CHANGE
Target $3.4
RAJA
Strong Buy
Antares Pharma maintained as a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur said the FDA's CRL on Antares Pharma (ATRS) XYOSTED was an unexpected and significant setback, but weakness in shares since the October disclosure effectively prices XYOSTED at zero, and substantially undervalues other development programs, especially ANDA products with Teva (TEVA). Wilbur is not writing-off XYSTED yet and is pushing out an expected launch to 2H19 from early 2018 previously, and is now discounting the probability of success at 50% versus 100% prior to the CRL. The analyst maintains asset values for Antares' non-XYOSTED assets are worth $2.50 per share using a sum-of-the-parts valuation and adjusted his price target to $3.40 from $4.20 on shares. Wilbur maintains a Strong Buy rating on Antares
10/23/17
MSCO
10/23/17
NO CHANGE
Target $26
MSCO
Overweight
Antares CRL should have limited read through to Amag, says Morgan Stanley
After Antares Pharma (ATRS) announced that it has received a FDA complete response letter about the new drug application for Xyosted due to two deficiencies related to clinical data, Morgan Stanley analyst Thomas Smith said the CRL should have limited read through to Amag Pharmaceuticals (AMAG), which has partnered with Antares for technology being used in subcutaneous Makena. The CRL is not related to the device or manufacturing, noted Smith, who adds that investor relief over the minimal Makena read through could lead to a rally in Amag shares following the recent weakness. He keeps 60% probability of success for Makena SC and maintains an Overweight rating on Amag shares.
PFE Pfizer
$40.53

0.87 (2.19%)

07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/17/18
HCWC
07/17/18
NO CHANGE
Target $42
HCWC
Buy
uniQure pullback on Pfizer study unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay notes that shares of uniQure (QURE) dropped 11% yesterday after Pfizer (PFE) initiated an "open-label, non-investigational product, multi-center, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX prophylaxis replacement therapy in moderate to severe adult Hemophilia B subjects who are negative for neutralizing antibodies to adeno-associated virus vector-spark100". This has been potentially misconstrued as the initiation of the Phase 3 study, suggesting competitive threats for uniQure earlier than anticipated, Chattopadhyay tells investors in a research note. However, this is not to be mistaken as a gene therapy Phase 3 program, as there is no gene therapy treatment cohort, the analyst adds. Further, Chattopadhyay points out that Pfizer's observation study is expected to be completed during November of 2020, which he believes puts uniQure at least a year, if not more, ahead. In addition, the analyst continues to believe that Pfizer is likely to encounter intellectual property headwinds given uniQure's patent asset protecting both the mPadua gene cassette and its method of use to treat hemoglobinopathies. He views the selloff yesterday in shares of uniQure as unwarranted and keeps a Buy rating on the name with a $42 price target.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

, GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

19:35
03/24/19
03/24
19:35
03/24/19
19:35
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

NFLX

Netflix

$361.00

-17.09 (-4.52%)

AMZN

Amazon.com

$1,764.96

-53.49 (-2.94%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GME

GameStop

$10.57

0.03 (0.28%)

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

CMCSK

Comcast

$0.00

(0.00%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

MAN

Manpower

$80.83

-5.02 (-5.85%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

LYFT

Lyft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 25

    Mar

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 10

    May

  • 12

    Jun

  • 27

    Oct

  • 29

    Mar

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

, GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

19:26
03/24/19
03/24
19:26
03/24/19
19:26
Periodicals
YouTube cancels plans for high-end dramas, comedies, Bloomberg reports »

Google-owned (GOOG;…

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

NFLX

Netflix

$361.00

-17.09 (-4.52%)

AMZN

Amazon.com

$1,764.96

-53.49 (-2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 27

    Mar

  • 29

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

ENTG

Entegris

$34.64

-1.2 (-3.35%)

19:23
03/24/19
03/24
19:23
03/24/19
19:23
Hot Stocks
Taiwan court finds Gudeng Precision infringes Entegris' reticle pod patent »

Entegris received an oral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MGTA

Magenta Therapeutics

$18.77

0.805 (4.48%)

19:21
03/24/19
03/24
19:21
03/24/19
19:21
Downgrade
Magenta Therapeutics rating change at Goldman Sachs »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$31.03

-0.05 (-0.16%)

, CMCSA

Comcast

$39.56

-0.49 (-1.22%)

16:20
03/24/19
03/24
16:20
03/24/19
16:20
Hot Stocks
Box Office Battle: 'Us' soars to historic $70M U.S. debut »

Comcast (CMCSA, CMCSK)…

T

AT&T

$31.03

-0.05 (-0.16%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$42.09

-1.915 (-4.35%)

LGF.A

Lionsgate

$15.14

-0.7 (-4.42%)

DIS

Disney

$108.30

-0.36 (-0.33%)

VIAB

Viacom

$25.27

-0.7 (-2.70%)

VIA

Viacom

$30.64

-0.66 (-2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 07

    May

  • 08

    May

  • 20

    May

  • 06

    Jun

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

16:07
03/24/19
03/24
16:07
03/24/19
16:07
Periodicals
Not enough evidence Trump obstructed justice, conspired with Russia, CNBC says »

Attorney General William…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

15:58
03/24/19
03/24
15:58
03/24/19
15:58
Periodicals
Mueller finds no Trump campaign-Russia conspiracy, Reuters reports »

Special Counsel Robert…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$119.21

-3.85 (-3.13%)

15:35
03/24/19
03/24
15:35
03/24/19
15:35
Hot Stocks
Ascendis Pharma announces top-line results from Phase 3 heiGHt trial »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

12:50
03/24/19
03/24
12:50
03/24/19
12:50
Periodicals
Trump, lawmakers awaiting details of Mueller's report, Reuters says »

U.S. lawmakers drew…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

, SPX

S&P 500

$0.00

(0.00%)

12:44
03/24/19
03/24
12:44
03/24/19
12:44
Periodicals
China refusing to concede on U.S. demands to ease curb on tech companies,FT says »

China is refusing to…

SPY

SPDR S&P 500 ETF Trust

$279.55

-5.08 (-1.78%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$175.60

-5.785 (-3.19%)

12:37
03/24/19
03/24
12:37
03/24/19
12:37
Periodicals
Alibaba acquires Israeli AR startup, Bloomberg reports »

Alibaba has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

12:34
03/24/19
03/24
12:34
03/24/19
12:34
Periodicals
Bayer CEO says team retains backing if supervisory board, Reuters says »

Bayer's management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

AAL

American Airlines

$30.60

-0.83 (-2.64%)

, BA

Boeing

$362.15

-10.54 (-2.83%)

12:31
03/24/19
03/24
12:31
03/24/19
12:31
Periodicals
American Airlines extends Boeing 737 Max flight cancellations, Reuters says »

American Airlines (AAL)…

AAL

American Airlines

$30.60

-0.83 (-2.64%)

BA

Boeing

$362.15

-10.54 (-2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

UBER

Uber

$0.00

(0.00%)

12:27
03/24/19
03/24
12:27
03/24/19
12:27
Periodicals
Uber to announce $3.1B deal to buy Careem, Bloomberg says »

Uber is set to announce a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDUS

Radius Health

$18.92

-0.39 (-2.02%)

12:17
03/24/19
03/24
12:17
03/24/19
12:17
Hot Stocks
Radius presents analysis from Phase 3 ACTIVE trial, data from TYMLOS studies »

Radius Health presented a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

13:09
03/23/19
03/23
13:09
03/23/19
13:09
Periodicals
Innovative Industrial Properties flying high, Barron's says »

American cannabis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

13:05
03/23/19
03/23
13:05
03/23/19
13:05
Periodicals
Investors missing how far Caterpillar dug into costs, Barron's says »

Caterpillar has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

MO

Altria Group

$55.90

-0.23 (-0.41%)

12:59
03/23/19
03/23
12:59
03/23/19
12:59
Periodicals
E-cigarettes not helping people quit smoking, Barron's says »

According to the CDC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

MAN

Manpower

$80.83

-5.02 (-5.85%)

, SABR

Sabre

$21.02

-0.62 (-2.87%)

12:51
03/23/19
03/23
12:51
03/23/19
12:51
Periodicals
Sabre, j2 Global among mid-cap stocks with sustainable dividends, Barron's says »

When it comes to…

MAN

Manpower

$80.83

-5.02 (-5.85%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 10

    May

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

, GME

GameStop

$10.57

0.03 (0.28%)

12:47
03/23/19
03/23
12:47
03/23/19
12:47
Periodicals
Gaming meets the cloud as investors scramble to catch up, Barron's says »

The cloud will eventually…

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

GME

GameStop

$10.57

0.03 (0.28%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

LYFT

Lyft

$0.00

(0.00%)

12:42
03/23/19
03/23
12:42
03/23/19
12:42
Periodicals
Investors should avoid booking ride when Lyft goes public, Barron's says »

Lyft will soon be going…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DIS

Disney

$108.30

-0.36 (-0.33%)

, AAPL

Apple

$191.11

-3.96 (-2.03%)

12:38
03/23/19
03/23
12:38
03/23/19
12:38
Periodicals
Streaming revolution too complicated, Barron's says »

The streaming revolution…

DIS

Disney

$108.30

-0.36 (-0.33%)

AAPL

Apple

$191.11

-3.96 (-2.03%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 11

    Apr

  • 25

    Apr

  • 08

    May

FB

Facebook

$164.25

-1.83 (-1.10%)

, GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

08:18
03/23/19
03/23
08:18
03/23/19
08:18
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$164.25

-1.83 (-1.10%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

TWTR

Twitter

$32.98

0.37 (1.13%)

GM

General Motors

$36.51

-0.84 (-2.25%)

AMD

AMD

$26.43

-1.47 (-5.27%)

INTC

Intel

$53.20

-1.41 (-2.58%)

MRVL

Marvell

$19.69

-1.11 (-5.34%)

MCHP

Microchip

$85.50

-1.83 (-2.10%)

MU

Micron

$41.68

-2.32 (-5.27%)

NVDA

Nvidia

$177.40

-6.52 (-3.55%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

  • 04

    Jun

  • 05

    Jun

  • 27

    Oct

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.